M.A. KURAPOV¹, O.M. BARANOVA^1,2, A.I. NILOV¹, Ya.V. VLASOV²

¹Samara Regional Clinical Hospital name after V.D. Seredavin, 159 Tashkentskaya Str., Samara, Russian Federation, 443095

²Samara State Medical University, 89 Chapaevskaya Str., Samara, Russian Federation, 443099

 Kurapov M.A. ― Neurologist, tel. (846) 956-05-44, e-mail: kurapovmichael@mail.ru, ORCID ID: 0000-0002-4584-3250

Baranova O.M. ― Neurologist, postgraduate student of the Neurology Department, tel. (846) 956-05-44, e-mail: steshina-om@mail.ru, ORCID ID: 0000-0001-8789-5326

Nilov A.I. ― Neurologist, Head of the Center for Demyelinating Diseases, tel. (846) 956-05-44, e-mail: a.nilov@icloud.com, ORCID ID: 0000-0003-4489-3800

Vlasov Ya.V. ― D. Sc. (medicine), Professor of the Neurology Department, tel. (846) 956-16-84 e-mail: sams99@inbox.ru, ORCID ID: 0000-0002-9471-9088

Objective ― to analyze the history and clinical examination of a group of patients receiving multiple sclerosis disease modifying therapeutics (MSDMT) in the Samara Region and to compare the efficiency of therapy with drugs of the I and II lines in real clinical practice

Material and methods. 69 patients were analyzed, a comparative study included 49 patients with a diagnosis of multiple sclerosis receiving high-dose interferons and natalizumab, the clinical status of the patients and anti-JCV antibody titers during natalizumab therapy were evaluated.

Results. Natalizumab therapy for the second line treatment of primary progredient multiple sclerosis was more effective in slowing the progression of EDSS disability and reducing the frequency of exacerbations.

Conclusion. MSDMT therapy is an effective measure to prevent exacerbations, leading to slowing the progression of disability. Currently, there is a need to ensure greater availability for patients of the second line drugs.

Key words: multiple sclerosis, multiple sclerosis disease modifying therapeutics (MSDMT), second-line drugs, primary progredient multiple sclerosis (PPMS), natalizumab.

(For citation: Kurapov M.A., Baranova O.M., Nilov A.I., Vlasov Ya.V. Patients with multiple sclerosis in the Samara Region and comparison of the efficiency of therapy with drugs of the I and II lines in real clinical practice. Practical Medicine. 2018)

REFERENCES

1. Autoimmune diseases in neurology. Klinicheskoe rukovodstvo, vol. 1, 2014. (In Russ.).
2. Shmidt T.E., Yahno N.N. Disseminated sclerosis. Rukovodstvo dlya vrachej, 2017. (In Russ.).
3. Tobias Derfuss, Ludwig Kappos PML risk and natalizumab: the elephant in the room. The Lancet Neurology, vol. 16, no 11, pp. 864-865.
4. Gusev E.I., Gekht A.B. Clinical recommendations for treatment of patients with multiple sclerosis the Project 2018, Russian committee of researchers of multiple sclerosis (RUCTRIMS) https://www.ructrims.org/edu.html last accessed 29.09.2018. (In Russ.)
5. Stangel M. et al. Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord, 2015, no. 8(1), pp. 3–13.
6. Havrdova E. et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. The Lancet Neurology, 2009, no. 8(3), pp. 254–260.
7. Silber E. et al. Ocrelizumab vs interferon β-1a in relapsing ms: two studies. Journal of Neurology, Neurosurgery & Psychiatry, 2016, no. 87(12), e1.51–e1.
8. Kappos L. et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016 Sep, no. 22(10), pp. 1297-305.
9. Vlasov, Y.V. et al. Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists. 2018. Zhurnal Nevrologii i Psikhiatrii Im. S. Korsakova, no. 118(8), (in Russ.)
10. Montalban, X. et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, no. 376(3), pp. 209–220.
11. Popova, E.V. et al. Primary progressive multiple sclerosis: current issues of timely diagnosis. Zhurnal Nevrologii i Psikhiatrii Im. S.S. Korsakova, 2017, no. 117(10), 11 p. (in Russ.)
12. Carroll W.M. 2017 McDonald MS diagnostic criteria: Evidence-based revisions. Multiple Sclerosis Journal, 2018, no. 24(2), pp. 92–95.